Restrictor slows early transcription elongation to render RNA polymerase II susceptible to termination at non-coding RNA loci
Guardado en:
| Publicado en: | bioRxiv (Jan 10, 2025) |
|---|---|
| Autor principal: | |
| Otros Autores: | , , |
| Publicado: |
Cold Spring Harbor Laboratory Press
|
| Materias: | |
| Acceso en línea: | Citation/Abstract Full text outside of ProQuest |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Resumen: | The eukaryotic genome is broadly transcribed by RNA polymerase II (RNAPII) to produce protein-coding messenger RNAs (mRNAs) and a repertoire of non-coding RNAs (ncRNAs). Whereas RNAPII is very processive during mRNA transcription, it terminates rapidly during synthesis of many ncRNAs, particularly those that arise opportunistically from accessible chromatin at gene promoters or enhancers. The divergent fates of mRNA versus ncRNA species raise many questions about how RNAPII and associated machineries discriminate functional from spurious transcription. The Restrictor complex, comprised of the RNA binding protein ZC3H4 and RNAPII-interacting protein WDR82, has been implicated in restraining the expression of ncRNAs. However, the determinants of Restrictor targeting and the mechanism of transcription suppression remain unclear. Here, we investigate Restrictor using unbiased sequence screens, and rapid protein degradation followed by nascent RNA sequencing. We find that Restrictor promiscuously suppresses early elongation by RNAPII, but this activity is blocked at most mRNAs by the presence of a 5' splice site. Consequently, Restrictor is a critical determinant of transcription directionality at divergent promoters and prevents transcriptional interference. Finally, our data indicate that rather than directly terminating RNAPII, Restrictor acts by reducing the rate of transcription elongation, rendering RNAPII susceptible to early termination by other machineries.Competing Interest StatementK.A. is a consultant to Syros Pharmaceuticals and Odyssey Therapeutics, is on the SAB of CAMP4 Therapeutics, and received research funding from Novartis not related to this work. Other authors have no interests to declare. |
|---|---|
| ISSN: | 2692-8205 |
| DOI: | 10.1101/2025.01.08.631787 |
| Fuente: | Biological Science Database |